GRI Bio, Inc. (GRI) Tuesday has priced its public offering at $3.60 per share, including Series Warrants, aiming to raise approximately $5 million before fees.
The offering includes 1,388,888 shares of common stock, with warrants exercisable at $3.20 per share. If fully exercised, the Series Warrants could generate an additional $13.3 million, though there is no guarantee of exercise. The offering is expected to close around April 2, 2025, subject to standard conditions, with H.C. Wainwright & Co. acting as the exclusive placement agent.
Proceeds will fund product development, working capital, and corporate expenses. The company's lead program, GRI-0621, targets idiopathic pulmonary fibrosis, with additional research into systemic lupus erythematosus. Despite a 52% stock decline in the past week, GRI Bio holds a market capitalization of $2.83 million and a current ratio of 3.43, indicating strong liquidity.
Separately, GRI Bio announced interim safety results from its Phase 2a study of GRI-0621, with an Independent Data Monitoring Committee supporting the trial's continuation. The company also secured two global patents for its Natural Killer T cell modulators, reinforcing its intellectual property.
Additionally, GRI Bio regained Nasdaq compliance regarding minimum bid price requirements and received stockholder approval for a reverse stock split, which could improve market interest and ensure continued listing. These developments align with the company's strategic growth initiatives.
GRI is currently trading at $3.0501 or 4.6844% lower on the Nasdaq Capital Market.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.